Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

Enrollment begins in phase III ophthalmic trials of difluprednate

Jan. 24, 2007

IND accepted for iCo-007 in diabetic macular edema

Jan. 24, 2007

Synergistic effects of triple antiangiogenic therapy in preclinical models of neovascularization

Jan. 23, 2007

New therapeutic agents for ocular disorders disclosed in recent patent literature

Jan. 22, 2007

Vismed begins phase III study in dry eye syndrome

Jan. 19, 2007

Lux receives orphan drug designations for ophthalmic products

Jan. 18, 2007

New treatment for macular degeneration reported by Nippon Soda

Jan. 18, 2007

U.S. orphan drug designation for LX-211 in uveitis

Jan. 17, 2007

Fovea licenses RdCVF therapy for retinal degeneration

Jan. 17, 2007

rEV-131 misses primary endpoint in phase II postcataract inflammation trial

Jan. 12, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 2, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...